Aimovig
NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine
December 11, 2020Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine
NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …
Aimovig reduces frequency of episodic migraines, five-year data reveals
October 6, 2020Manufacturing and Production, Research and Development Aimovig
Amgen and Novartis have revealed new five-year Phase 2 data during the Migraine Trust Virtual Symposium for their calcitonin gene-related …
NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland
September 26, 2019Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma
NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …
4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine
September 9, 2019Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma
Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …
NICE rejects Novartis’ Aimovig migraine injection for NHS use
January 10, 2019Sales and Marketing Aimovig, NICE, Novartis, migraine, pharma
It’s disappointing news for Novartis as NICE revealed that it had decided not to recommend Aimovig (erenumab) for routine NHS …
Novartis migraine prevention drug scores EU approval
July 31, 2018Manufacturing and Production, Sales and Marketing Aimovig, Europe, Novartis, migraine, pharma
Novartis is celebrating the news that its calcitonin gene-related peptide receptor (CGRP-R) pathway therapy Aimovig (erenumab) has been approved by …
Amgen/Novartis migraine med gets CHMP nod
June 4, 2018Sales and Marketing Aimovig, Amgen, Novartis, biotech, drugs, pharma, pharmaceutical
Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …
Amgen and Novartis’ Aimovig shines in migraine at Phase 3
April 18, 2018Research and Development Aimovig, Amgen, Novartis, migraine, pharma
Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …
